AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 81 min read$TENX

ADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $1.6M of TENX (indirect holdings)

ADAR1 Capital Management, LLC purchased 900,000 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at $1.78 ($1.60M total) on 2026-09-03. Filed jointly with Schneeberger Daniel (10% owner).

Original reporting
SEC EDGAR · ADAR1 Capital Management, LLC, Schneeberger Daniel
Published Sep 8, 2026, 9:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TENX
Neutral
medium confidence
Mentioned
$TENX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TENXNeutralLow
01

Why it matters

The disclosed purchase adds to ADAR1's stake, indicating continued confidence but limited market impact.

02

Market read

Small insider buy; modest relevance for traders monitoring TENX.

03

What to watch

The purchase is indirect and may reflect broader fund rebalancing rather than company-specific optimism.

Relevance 7/10Novelty 5/10Timing: post-filing on 2026-09-08

Background

Form 4 filings disclose insider transactions; ADAR1 Capital Management is a 10% owner of TENX.

Company-level read

Ticker impact

$TENXNeutralMedium confidence
Context

SEC Form 4 shows ADAR1 Capital Management bought 900,000 TENX shares at $1.7824, totaling $1.6M, raising its stake to 6.5M shares.

Expected impact

Potential slight upside pressure, unlikely to move price materially.

Evidence & confidence

A $1.6M buy by a 10% owner is a positive signal, but the amount is small for a listed biotech.

Market effects

Sector

Minor signal for biotech sector; no broader impact.

Regional

U.S. market only; negligible regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

Insider buying could be a routine portfolio adjustment, not a strong endorsement.

Key entities

  • Investor
    ADAR1 Capital Management, LLC

    10% owner of TENX filing a Form 4 purchase.

  • Company
    TENAX THERAPEUTICS, INC.

    Biotech firm listed under ticker TENX.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TENX insider trading history →

Related articles

SEP 4
$TENXMedAI 8/10

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

Tenax Therapeutics (TENX) reported that its Phase 3 LEVEL trial for TNX-103 missed primary endpoints but showed a 26.3-meter benefit in a prespecified subgroup of patients with severe baseline impairment. The company has $118.0 million in cash and plans to seek regulatory input for an enriched LEVEL-2 trial. Safety data was comparable between treatment and placebo groups.

insidermonkey.com2 min
AUG 31
$TENXHighAI 9/10

Why is Tenax Therapeutics stock volatile today?

Tenax Therapeutics (TENX) stock rose 3.8% in pre-market trading after presenting additional Phase 3 trial data at the European Society of Cardiology Congress. The data showed favorable treatment effects for TNX-103 in patients with severe pulmonary hypertension due to heart failure. Several Wall Street firms initiated coverage with Buy ratings and price targets of $35-$40. The company has $118 million in cash, providing a runway through Q2 2028.

investing.com2 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Presents Additional Phase 3 LEVEL Data Showing TNX-103 Benefits in PH-HFpEF Patients With Lower Baseline Walk Distance

Tenax Therapeutics (TENX) presented additional Phase 3 LEVEL trial data showing TNX-103 improved 6MWD, NT-proBNP, and RVSP in PH-HFpEF patients with lower baseline walk distance. The company plans to enrich the LEVEL-2 population based on these results. TNX-103 showed a 26.3m 6MWD improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction vs. placebo in this subgroup.

quiverquant.com3 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Tenax Therapeutics presented Phase 3 LEVEL trial results at ESC Congress 2026. TNX-103 showed significant improvements in patients with PH-HFpEF and baseline 6MWD below 333 meters, including a 26.3m walk distance improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction. The company plans to enrich the population for the next study.

finance.yahoo.com2 min